Heartbeam, Inc. - Common Stock (BEAT)
1.0300
-0.0800 (-7.21%)
NASDAQ · Last Trade: Aug 17th, 5:55 PM EDT
Detailed Quote
| Previous Close | 1.110 |
|---|---|
| Open | 1.110 |
| Bid | 1.030 |
| Ask | 1.050 |
| Day's Range | 1.030 - 1.178 |
| 52 Week Range | 0.9101 - 3.480 |
| Volume | 79,324 |
| Market Cap | 35.29M |
| PE Ratio (TTM) | 2.191 |
| EPS (TTM) | 0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 113,037 |
Chart
About Heartbeam, Inc. - Common Stock (BEAT)
Heartbeam Inc is a healthcare technology company focused on developing innovative solutions for cardiac care. The company specializes in advanced heart monitoring technologies, particularly through its proprietary platform that combines telemedicine with electrocardiogram (ECG) technology. Heartbeam's products aim to provide healthcare professionals and patients with real-time monitoring and analysis of heart health, facilitating early detection of potential issues and improving patient outcomes. By leveraging cutting-edge technology, Heartbeam seeks to enhance the management of cardiovascular diseases and promote more informed healthcare decisions. Read More
News & Press Releases
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total to 21 worldwide, and multiple industry awards. Q2 R&D expenses rose to $3.3 million from $2.8 million a year ago, while G&A fell to $1.7 million from $2.2 million. Net loss was $5.0 million, flat year-over-year. Cash, equivalents, and short-term investments totaled $5.1 million at quarter-end.
Via Investor Brand Network · August 14, 2025
HeartBeam Inc. reports Q2 2025 results with a net loss of $5M, beating EPS estimates. FDA clearance for ECG tech expected by year-end amid steady cash burn. Stock shows mixed reaction.
Via Chartmill · August 13, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025.
By HeartBeam, Inc. · Via Business Wire · August 13, 2025
HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care
Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space ( https://ibn.fm/0TAG4 ). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings.
Via Investor Brand Network · August 6, 2025
HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics
HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology ( https://ibn.fm/6xni4 ). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S. and international patents, with additional applications pending.
Via Investor Brand Network · August 5, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Aug. 13 Call to Discuss Q2 Results and Provide Business Updates
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, will hold a conference call Aug. 13, 2025, at 4:30 p.m. Eastern to discuss second-quarter results for the period ended June 30, 2025. The company will also provide updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. CEO Robert Eno and CFO Timothy Cruickshank will host the call, followed by a question-and-answer session.
Via Investor Brand Network · July 30, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Wednesday, August 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call.
By HeartBeam, Inc. · Via Business Wire · July 30, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2025 Innovation Award for Remote Cardiac Diagnostics
HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, has received the Innovation Award in Remote Cardiac Diagnostics from the 2025 Medical Device Network Excellence Awards. The honor recognizes HeartBeam’s FDA-cleared 3D ECG technology, which enables clinical-grade arrhythmia diagnostics in non-clinical settings via a compact, cable-free device. The synthesized 12-lead ECG software is under FDA review, with commercialization planned upon clearance. This award adds to HeartBeam’s growing list of accolades for its leadership in remote cardiac care.
Via Investor Brand Network · July 22, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has been awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards. The award honors HeartBeam’s groundbreaking, FDA-cleared electrocardiogram (ECG) technology that enables clinical-grade diagnostics for arrhythmia assessment outside of traditional healthcare settings, expanding access to timely and actionable cardiac care.
By HeartBeam, Inc. · Via Business Wire · July 22, 2025
BioMedNewsBreaks — Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’
HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking,” reads a recent article. “As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.”
Via Investor Brand Network · July 8, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Present at iAccess Alpha Virtual Summer Conference
HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. The executives will also conduct virtual one-on-one meetings with institutional investors during the event.
Via Investor Brand Network · June 23, 2025
RALEIGH, NC / ACCESS Newswire / June 23, 2025 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference will take place on June 24-25, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities. The lineup has recently been updated to include additional presenters.
Via ACCESS Newswire · June 23, 2025
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam’s plans to improve access to timely, remote cardiac care.
Via Investor Brand Network · June 20, 2025
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures Two New Patents Advancing 3D ECG and Cardiac Monitoring Technology
HeartBeam (NASDAQ: BEAT), announced the issuance of two new U.S. patents that strengthen its intellectual property portfolio and support the company’s expansion in remote cardiac diagnostics. The new patents protect core technologies behind HeartBeam’s compact, cable-free 3D ECG device and its rhythm analysis algorithm capable of identifying arrhythmias through continuous signal input.
Via Investor Brand Network · June 18, 2025
RALEIGH, NC / ACCESS Newswire / June 18, 2025 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference will take place on June 24-25, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.
Via ACCESS Newswire · June 18, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with AccurKardia, a leader in automated ECG diagnostics, to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s cable-free, credit card-sized 3D ECG device. The partnership unites two innovators in ambulatory cardiac monitoring to create a more scalable, accessible solution for arrhythmia detection and management.
Via Investor Brand Network · June 17, 2025
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy Cruickshank, Chief Financial Officer, will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Eno and Cruickshank will also host virtual one-on-one meetings with institutional investors during the event.
By HeartBeam, Inc. · Via Business Wire · June 17, 2025
HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’
HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.
Via Investor Brand Network · June 16, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG
HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society’s annual meeting in San Diego, validate HeartBeam’s compact, patient-friendly ECG technology.
Via Investor Brand Network · June 16, 2025
Via Benzinga · June 16, 2025
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reported Q1 2025 Results, Advanced Toward Commercialization Following VALID-ECG Study Success
HeartBeam (NASDAQ: BEAT) reported financial results and operational highlights for the first quarter of 2025, marking significant progress toward commercialization of its 12-lead ECG synthesis software. The company successfully met clinical endpoints in its VALID-ECG pivotal study, demonstrating a 93.4% diagnostic agreement with standard ECGs, and engaged in productive discussions with the FDA on its 510(k) submission.
Via Investor Brand Network · June 13, 2025